Research

Health

In space, NASA heard astronaut’s immune system scream

By Associated Press

Cambridge flood

Business

Hurricanes, droughts, and wildfires: How biopharma is girding for climate change

By Kate Sheridan

advertisement

Something ventured illo

Biotech

Something Ventured: Finch Therapeutics and three other startups got venture funding a year ago. Did it help them do what they said it would?

By Kate Sheridan

advertisement

John V. Oyler, CEO of BeiGene

Biotech

For a Chinese cancer drug developer, Bristol-Celgene deal is poised to have big ripple effects

By Rebecca Robbins

Macrophage - glioblastoma

Health

An early study ‘infuses hope’ back into attempts to use immunotherapy to treat brain cancer

By Andrew Joseph

Sean Parker

Heavyweights

Billionaire Sean Parker calls China’s gene-edited babies ‘Sputnik 2.0,’ praises FDA, and offers career advice for millennials

The capitol at sunrise

The Pharmalot View

Prepare for grilling: 7 questions for 7 pharma execs who’ll testify before Congress about prices

By Ed Silverman

advertisement

CRISPR/Cas9 molecular structure

First Opinion

Why my patient advocacy organization is investing in CRISPR

By Debra Miller

advertisement

Alexandria Ocasio-Cortez

Biotech

A tweet from Alexandria Ocasio-Cortez prompts a deeper debate over how drugs are made

By Damian Garde, Rebecca Robbins, and Adam Feuerstein

A self-righting capsule

In the Lab

Scientists take a page from tortoises to design a new type of drug delivery

By Megan Thielking

National Institutes of Health Director Dr. Francis Collins

Politics

NIH asks inspector general to investigate 12 allegations of foreign influence in U.S. research

European Space Agency

In the Lab

A Mars rover is named after pioneering DNA scientist Rosalind Franklin

By Megan Thielking

Sarepta - hearing

Biotech

Solid Biosciences to soldier on as initial muscular dystrophy gene therapy results disappoint

By Matthew Herper

Three Identical Strangers promo

First Opinion

‘Three Identical Strangers’: It’s not too late to address the ethical violations

By Karen Glanz and Holly Fernandez Lynch

Dog

Pharmalot

Drug maker sues FDA over a dog study — and its stock goes into a tailspin

By Ed Silverman

In the Lab

By decoding flickering brain signals, scientists envision a new way to detect consciousness

By Eric Boodman

Infusion at home

First Opinion

Cancer treatment at home is safe, effective, and closer to happening than you think

By Nathan R. Handley and Justin E. Bekelman

Pink and blue capsules

First Opinion

Synthetic control arms can save time and money in clinical trials

By Jen Goldsack

Iowa Baby Brothers

Don't Miss

With time ticking away, clinicians scramble to save newborn twins from the disease that took their brother

By Rebecca Robbins

Josh Hillman

Health

‘We’re still waiting’: As cystic fibrosis drugs deliver new hope, not everyone is being swept up by scientific progress

By Andrew Joseph

Dana Farber Cancer Institute.

In the Lab

Dana-Farber heads to court to add researcher on immunotherapy patents

By Elizabeth Cooney

Gene editing in lab

First Opinion

CRISPR-Cas9 commercialization may be slowed by delivery and manufacturing challenges

By Jim Burns

Brain is a puzzle

Health

To improve mental health treatments, scientists try to dissect the pieces that make them work

By Megan Thielking

Elderly hands

First Opinion

A new NIH rule won’t be enough to make clinical research more inclusive

By Louise Aronson

Archery targets

First Opinion

Multi-target drugs should be in the pharma pipeline along with precision drugs

By Harris A. Gelbard

Michael Deem photo illustration

Exclusive

American scientist played more active role in ‘CRISPR babies’ project than previously known

By Jane Qiu

Pills in blister pack

First Opinion

It’s time to get serious about the economics of expanded access

By Peter J. Pitts

In the Lab

After ghoulish allegations, a brain-preservation company seeks redemption

By Sharon Begley

Real world clinical trial

First Opinion

Real-world evidence is changing the way we study drug safety and effectiveness

By Nancy A. Dreyer